FrexalimAB in preservation of endogenous insULIN secretion compared to placebo in adUlts and adolescents on top of inSulin therapy (FABULINUS)

FrexalimAB in preservation of endogenous insULIN secretion compared to placebo in adUlts and adolescents on top of inSulin therapy (FABULINUS)

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
The goal of this Phase 2 study is to assess safety and efficacy of frexalimab to preserve β-cell function in participants with newly diagnosed type 1 diabetes (T1D). In Part A, an exploratory part, adults (ages 18-35) will be treated with either high dose frexalimab, or placebo (inactive study drug). In Part B, adolescents and young adults (ages 12-21) will be treated with 3 dose levels of frexalimab or placebo.

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.